

ARK-153US1

Appl. No.: 10/774,021
Non-Compliant Amendment Dated January 24, 2006
Reply to Non-Compliance of January 18, 2006

Amendments to the Claims: This listing of claims will replace all prior versions, and listings,
of claims in the application

Listing of Claims:

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Canceled)
20. (Canceled)
21. (Canceled)
22. (Canceled)
23. (Canceled)
24. (Canceled)
25. (Canceled)
26. (Canceled)
27. (Canceled)
28. (Canceled)

ARK-153US1

Appln. No.: 10/774,021
Non-Compliant Amendment Dated January 24, 2006
Reply to Non-Compliance of January 18, 2006

- 29. (Canceled)
- 30. (Canceled)
- 31. (Canceled)
- 32. (Canceled)
- 33. (Canceled)
- 34. (Canceled)
- 35. (Canceled)
- 36. (Canceled)
- 37. (Canceled)
- 38. (Canceled)
- 39. (Canceled)
- 40. (Canceled)
- 41. (Canceled)
- 42. (Canceled)
- 43. (Canceled)
- 44. (Canceled)
- 45. (canceled)

46. (Currently Amended) A composition comprising glucosamine and an active egg fraction, wherein the active egg fraction is purified from an egg obtained from an egg-producing animal that has been hyperimmunized with an immunogenic vaccine, said immunogenic vaccine comprising antigens selected from the group consisting of bacterial, viral, protozoan, fungal and cellular immunogens and mixtures thereof, and wherein said active egg fraction further comprises supranormal levels of an anti-inflammatory composition.

47. (Previously Presented) The composition of claim 46 wherein the active egg fraction comprises egg yolk.

48. (Previously Presented) The composition of claim 47 wherein the active egg fraction comprises a partially purified anti-inflammatory fraction of the egg, wherein said fraction is purified from the egg yolk.

ARK-153US1

Appln. No.: 10/774,021
Non-Compliant Amendment Dated January 24, 2006
Reply to Non-Compliance of January 18, 2006

49. (Currently Amended) The composition of claim 46 wherein the glucosamine is selected from the group ~~comprising~~ consisting of glucosamine ~~HCl~~ HCl and glucosamine sulfate.

50. (Previously Presented) The composition of claim 46 wherein the amount of glucosamine comprises between approximately 10 milligrams and 5 grams.

51. (Previously Presented) The composition of claim 46 wherein the immunogenic vaccine comprises immunogens selected from the group consisting of: *Escherichia coli*, *Escherichia coli* (Aerobacter), *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Shigella dysenteriae*, *Salmonella enteritidis*, *Staphylococcus epidermidis*, *Staphylococcus simulans*, *Streptococcus pyogenes*, type 1, *Streptococcus pyogenes*, type 3, *Streptococcus pyogenes*, type 5, *Streptococcus pyogenes*, type 8, *Streptococcus pyogenes*, type 12, *Streptococcus pyogenes*, type 14, *Streptococcus pyogenes*, type 18, *Streptococcus pyogenes*, type 22, *Proteus vulgaris*, *Streptococcus agalactiae*, *Streptococcus mitis*, *Streptococcus mutans*, *Streptococcus salivarius*, *Streptococcus sanguis*, *Streptococcus pneumoniae*, *Propionibacterium acnes* and *Haemophilis influenzae*

52. (Withdrawn) A method for reducing serum fibrinogen levels in a subject, the method comprising administering to the subject an effective amount of a composition comprising glucosamine and an active egg fraction wherein the active egg fraction is purified from an egg obtained from an egg-producing animal which has been hyperimmunized with an immunogenic vaccine, said immunogenic vaccine comprising antigens selected from the group consisting of bacterial, viral, protozoan, fungal and cellular immunogens and mixtures thereof.

53. (Withdrawn) The method of claim 52 wherein the effective amount of glucosamine comprises between approximately 10 milligrams and 5 grams.

54. (Withdrawn) The method of claim 52 wherein the composition is administered by a method selected from the group consisting of parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, intranasally, orally and topically.

55. (Withdrawn) The method of claim 52 wherein the active egg fraction is dried to form a dried powder.

ARK-153US1

Appl. No.: 10/774,021
Non-Compliant Amendment Dated January 24, 2006
Reply to Non-Compliance of January 18, 2006

56. (Withdrawn) A method for reducing or preventing the onset of rheumatoid arthritis in a subject, the method comprising administering to the subject an effective amount of a composition comprising glucosamine and an active egg fraction wherein the active egg fraction is purified from an egg an egg-producing animal which has been hyperimmunized with an immunogenic vaccine, said immunogenic vaccine comprising antigens selected from the group consisting of bacterial, viral, protozoan, fungal and cellular immunogens and mixtures thereof.

57. (Withdrawn) The method of claim 56 wherein the effective amount of glucosamine comprises between approximately 10 milligrams and 5 grams.

58. (Withdrawn) The method of claim 56 wherein the composition is administered by a method selected from the group consisting of parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, intranasally, orally and topically.

59. (Withdrawn) The method of claim 56 wherein the active egg fraction is dried to form a dried powder.